Conferring Ti‐Based MOFs with Defects for Enhanced Sonodynamic Cancer Therapy

• DOI: 10.1002/adma.202100333
• Publication Date: 2021-04-01T07:56:46Z
• Authors: Shuang Liang; Xiao Xiao; Lixin Bai; Bin Liu; Meng Yuan; Ping'an Ma; Maolin Pang; Ziyong Cheng; Jun Lin
• Keywords: Titanium; Cell Line, Tumor; Ultrasonic Therapy; Humans; Nanoparticles; Reactive Oxygen Species; 01 natural sciences; Metal-Organic Frameworks; 0104 chemical sciences; 3. Good health

AbstractThe development of highly efficient, multifunctional, and biocompatible sonosensitizer is still a priority for current sonodynamic therapy (SDT). Herein, a defect‐rich Ti‐based metal–organic framework (MOF) (D‐MOF(Ti)) with greatly improved sonosensitizing effect is simply constructed and used for enhanced SDT. Compared with the commonly used sonosensitizer TiO2, D‐MOF(Ti) results in a superior reactive oxygen species (ROS) yield under ultrasound (US) irradiation due to its narrow bandgap, which principally improves the US‐triggered electron–hole separation. Meanwhile, due to the existence of Ti3+ ions, D‐MOF(Ti) also exhibits a high level of Fenton‐like activity to enable chemodynamic therapy. Particularly, US as the excitation source of SDT can simultaneously enhance the Fenton‐like reaction to achieve remarkably synergistic outcomes for oncotherapy. More importantly, D‐MOF(Ti) can be degraded and metabolized out of the body after completion of its therapeutic functions without off‐target toxicity. Overall, this work identifies a novel Ti‐familial sonosensitizer harboring great potential for synergistic sonodynamic and chemodynamic cancer therapy.